22 Noviembre 2023 Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH Ver enlace
22 Noviembre 2023 Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2 Ver enlace
31 Octubre 2023 FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade Leer más...
